Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression
- 1 December 2003
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 362 (9400) , 1979-1980
- https://doi.org/10.1016/s0140-6736(03)15018-0
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 2003
- TRIZAL study: switching from successful HAART to TrizivirTM (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence resultsHIV Medicine, 2003
- Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNAAIDS, 2001
- Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral TherapyScience, 1997